Introduction Enterococcus faecium is a commensal microorganism that can cause infections
such as bacteremia. Incidence of ampicillin-resistant and vancomycin-susceptible E …

Scope This position paper describes the view adopted by EUCAST on the role of
daptomycin in the treatment of serious infections caused by Enterococcus species …

Background Acinetobacter baumannii has been recognized as a cause of nosocomial
infection. To date, polymyxins, the last-resort therapeutic agents for carbapenem-resistant A …

Background: Ampicillin resistant and glycopeptide susceptible Enterococcus faecium
bloodstream infection (GSEF-BSI) incidence has risen. However, the treatment of choice …

Tigecycline was previously considered to have activity against vancomycin-resistant
Enterococcus (VRE) isolates, but the optimal dose was not clarified. Thus, this study …

To explore whether susceptibility testing with antibiotic combinations at pharmacokinetically
derived concentration ratios is predictive of the antimicrobial effect, a Staphylococcus aureus …

Bacteriophage endolysins are peptidoglycan hydrolases composed of cell binding domain
(CBD) and an enzymatically active domain. A phage endolysin CBD can be used for …

Background Daptomycin (DAP) is a cyclic lipopeptide antibiotic with in vitro, concentration-
dependent bactericidal activity against many clinically relevant gram-positive organisms …

RESUMEN (en español) Las bacterias resistentes a antibióticos suponen una seria
amenaza para la salud pública, especialmente cuando afectan a antimicrobianos de última …

Daptomycin was approved by Health Canada (HC) in 2007 for the treatment of complicated
skin and skin structure infections (CSSSIs) at 4 mg/kg/day, and for Staphylococcus aureus …